NeuroMetrix, Inc. (NASDAQ:NURO) Short Interest Update

NeuroMetrix, Inc. (NASDAQ:NURO) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 42,400 shares, an increase of 168.4% from the October 31st total of 15,800 shares. Based on an average daily trading volume, of 18,200 shares, the short-interest ratio is currently 2.3 days. Currently, 2.9% of the company’s stock are sold short.

NeuroMetrix Trading Up 0.3 %

NURO stock opened at $4.26 on Thursday. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The stock has a market cap of $8.69 million, a P/E ratio of -0.93 and a beta of 2.29. The stock’s fifty day simple moving average is $4.06 and its two-hundred day simple moving average is $3.83.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million for the quarter. During the same period in the prior year, the firm posted ($1.66) EPS.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on NeuroMetrix in a research note on Thursday. They issued a “sell” rating on the stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.